ABSTRACT
The Covid-19 pandemic caused millions of death worldwide. Vaccines have been developed but patients on immunosuppressive therapy are less likely to respond. This study aimed to investigate the efficacy of Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma, treated with anti-CD20 monoclonal antibodies. Only one of 28 lymphoma patients (3.6%) developed a seropositive response compared to 100% (28 of 28) of the healthy volunteers. The low levels of CD19+ lymphocytes among the lymphoma patients suggest that the anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients, once B cells are repopulated.
Fuente: Experimental Hematology
Available online 22 December 2021
